A Study to Assess Pulsed Inhaled Nitric Oxide in Subjects With Pulmonary Fibrosis at Risk for Pulmonary Hypertension (REBUILD)
A Randomized, Double-Blind, Placebo-Controlled Dose Escalation and Verification Clinical Study to Assess the Safety and Efficacy of Pulsed Inhaled Nitric Oxide (iNO) in Subjects at Risk of Pulmonary Hypertension Associated With Pulmonary Fibrosis on Long Term Oxygen Therapy (Part 1 and Part 2) - REBUILD
Sponsor: Bellerophon Pulse Technologies
Terminated
The trial did not meet its primary endpoint, hence was terminated due to futility.
Other terminated trials from Bellerophon Pulse Technologies
More terminations from Bellerophon Pulse Technologies
This PHASE3 trial investigates Pulmonary Fibrosis and Pulmonary Hypertension and is currently terminated or withdrawn. Bellerophon Pulse Technologies leads this study, which shows 29 recorded versions since 2020 — indicating substantial longitudinal coverage. Heart and vascular conditions benefit from the kind of long-term tracking this trial provides.
Status Flow
Change History
29 versions recorded-
Sep 2025 — Present [monthly]
Terminated PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Terminated PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Terminated PHASE3
-
Aug 2023 — Jul 2024 [monthly]
Terminated PHASE3
Status: Active Not Recruiting → Terminated
-
Mar 2023 — Aug 2023 [monthly]
Active Not Recruiting PHASE3
▶ Show 24 earlier versions
-
Feb 2023 — Mar 2023 [monthly]
Active Not Recruiting PHASE3
Status: Recruiting → Active Not Recruiting
-
Jan 2023 — Feb 2023 [monthly]
Recruiting PHASE3
-
Nov 2022 — Jan 2023 [monthly]
Recruiting PHASE3
-
Sep 2022 — Nov 2022 [monthly]
Recruiting PHASE3
-
Apr 2022 — Sep 2022 [monthly]
Recruiting PHASE3
-
Mar 2022 — Apr 2022 [monthly]
Recruiting PHASE3
-
Dec 2021 — Mar 2022 [monthly]
Recruiting PHASE3
-
Sep 2021 — Dec 2021 [monthly]
Recruiting PHASE3
Phase: PHASE2_PHASE3 → PHASE3
-
Jun 2021 — Sep 2021 [monthly]
Recruiting PHASE2_PHASE3
-
Jan 2021 — Jun 2021 [monthly]
Recruiting PHASE2_PHASE3
-
Dec 2020 — Jan 2021 [monthly]
Recruiting PHASE2_PHASE3
Status: Active Not Recruiting → Recruiting
-
Nov 2020 — Dec 2020 [monthly]
Active Not Recruiting PHASE2_PHASE3
-
Sep 2020 — Nov 2020 [monthly]
Active Not Recruiting PHASE2_PHASE3
-
Jul 2020 — Sep 2020 [monthly]
Active Not Recruiting PHASE2_PHASE3
Phase: PHASE2 → PHASE2_PHASE3
-
Feb 2020 — Jul 2020 [monthly]
Active Not Recruiting PHASE2
Status: Recruiting → Active Not Recruiting
-
Sep 2019 — Feb 2020 [monthly]
Recruiting PHASE2
-
Jun 2019 — Sep 2019 [monthly]
Recruiting PHASE2
-
Feb 2019 — Jun 2019 [monthly]
Recruiting PHASE2
-
Aug 2018 — Feb 2019 [monthly]
Recruiting PHASE2
-
Jun 2018 — Aug 2018 [monthly]
Recruiting PHASE2
-
May 2018 — Jun 2018 [monthly]
Recruiting PHASE2
-
Mar 2018 — May 2018 [monthly]
Recruiting PHASE2
-
Jan 2018 — Mar 2018 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Sep 2017 — Jan 2018 [monthly]
Not Yet Recruiting PHASE2
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Bellerophon Pulse Technologies
For direct contact, visit the study record on ClinicalTrials.gov .